CTIC CTI BioPharma Corp.

3.31
-0.03  -1%
Previous Close 3.34
Open 3.36
Price To book 3.28
Market Cap 142270996
Shares 42,982,174
Volume 149,228
Short Ratio 1.31
Av. Daily Volume 195,629

SEC filingsSee all SEC filings

  1. 8-K - Current report 171108300
  2. 8-A12G/A [Amend] - Registration of securities [Section 12(g)] 171102606
  3. 8-K - Current report 171102584
  4. 8-K - Current report 171063794
  5. 8-K - Current report 171045807

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2018. Noted August 2, 2017 that enrollment has completed.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
PERSIST-2 data released August 2016. One of two primary endpoints met. Additional trial commenced enrollment - noted August 1, 2017.
Pacritinib - PAC203
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. ETFs with exposure to CTI BioPharma Corp. : October 16, 2017
  2. CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
  3. CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
  4. CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference
  5. Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT
  6. CTI BioPharma posts 2Q profit
  7. CTI BioPharma Reports Second Quarter 2017 Financial Results
  8. Investor Network: CTI BioPharma Corp. to Host Earnings Call
  9. CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma
  10. CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
  11. CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017
  12. CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
  13. CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia
  14. CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
  15. ETFs with exposure to CTI BioPharma Corp. : June 8, 2017
  16. CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock
  17. CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock
  18. CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations
  19. Edited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT

SEC Filings

  1. 8-K - Current report 171108300
  2. 8-A12G/A [Amend] - Registration of securities [Section 12(g)] 171102606
  3. 8-K - Current report 171102584
  4. 8-K - Current report 171063794
  5. 8-K - Current report 171045807
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171006581
  7. 8-K - Current report 171005201
  8. 8-K - Current report 171005139
  9. 8-K - Current report 17986793
  10. 8-K - Current report 17978649